Pfizer preparing Inflectra launch

Pfizer Inc. (NYSE:PFE) said it will launch Inflectra infliximab-dyyb, a biosimilar of Remicade infliximab, in late November at a 15% discount to Remicade's wholesale acquisition cost. Inflectra would be the first Remicade biosimilar launched in the U.S.

Johnson & Johnson (NYSE:JNJ) markets Remicade. In a statement, J&J said it will continue to defend its IP covering the drug, and considers Pfizer's action to be an at-risk launch. J&J said it will compete with the biosimilar "through a variety of contracting options, discounts and rebates." ...